Innate Pharma Presents IPH6501 Preclinical Antitumor Data at EHA Congress

Innate Pharma presented promising preclinical data for IPH6501, a novel NK cell engager targeting CD20, at the 2025 European Hematology Association Congress, demonstrating potent antitumor activity in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). IPH6501 showed enhanced efficacy when combined with R-CHOP, the current standard of care, including in rituximab-resistant tumor models, suggesting potential to improve treatment outcomes for relapsed or refractory B-cell non-Hodgkin lymphoma patients. The therapy is currently being evaluated in a Phase 1/2 clinical trial for safety and efficacy in relapsed/refractory CD20+ B-cell NHL. Analysts have responded positively, with an average “Outperform” brokerage rating and a significant projected stock price upside. Innate Pharma leverages its proprietary ANKET® platform for developing IPH6501 and collaborates with major biopharmaceutical firms, underscoring its clinical-stage biotech leadership. These findings support further clinical development and combination therapy exploration in B-NHL to address significant unmet medical needs.